In a 75-year-old patient with osteoporosis on Prolia (denosumab) and chronic kidney disease, who has hypercalcemia (serum calcium 11 mg/dL) and markedly elevated PTH (175 pg/mL), what management steps should be taken?

Stop Prolia Immediately and Investigate for Tertiary Hyperparathyroidism

Your patient's combination of hypercalcemia (calcium 11 mg/dL) with markedly elevated PTH (175 pg/mL) while on Prolia (denosumab) in the setting of chronic kidney disease represents a paradoxical and concerning clinical picture that requires immediate discontinuation of denosumab and urgent evaluation for tertiary hyperparathyroidism.

Understanding the Clinical Paradox

This presentation is highly unusual because:

• Denosumab typically causes hypocalcemia, not hypercalcemia, especially in CKD patients 1
• The elevated PTH with hypercalcemia suggests autonomous parathyroid function (tertiary hyperparathyroidism) rather than appropriate physiologic response
• In CKD, denosumab commonly triggers secondary hyperparathyroidism as a compensatory response to hypocalcemia 2, 1, but your patient has the opposite problem

Immediate Management Steps

1. Discontinue Prolia

• Do not administer the next scheduled dose
• The hypercalcemia is likely driven by tertiary hyperparathyroidism, not the denosumab itself
• Continuing denosumab will complicate calcium management and potentially worsen PTH elevation

2. Confirm and Characterize the Hypercalcemia

• Repeat ionized calcium (more accurate in CKD than total calcium)
• Check 25-OH vitamin D and 1,25-dihydroxy vitamin D levels
• Obtain phosphate level
• Assess for symptoms: polyuria, polydipsia, cognitive changes, constipation, bone pain

3. Evaluate for Tertiary Hyperparathyroidism

• Order parathyroid imaging (sestamibi scan and/or ultrasound)
• Review trend of PTH levels over time—progressive elevation suggests autonomous parathyroid disease
• The combination of PTH 175 pg/mL with calcium 11 mg/dL in CKD strongly suggests tertiary hyperparathyroidism 3

4. Acute Hypercalcemia Management

• Hydration: IV normal saline to restore volume and enhance renal calcium excretion (if kidney function permits)
• Adjust dialysate calcium if on dialysis: use low-calcium dialysate (2.5 mEq/L)
• Avoid thiazide diuretics and calcium supplements
• Stop vitamin D supplementation temporarily 3

Definitive Treatment Considerations

For Tertiary Hyperparathyroidism with Hypercalcemia:

Calcimimetics (Cinacalcet) are first-line medical therapy 3:

• Directly suppresses PTH secretion
• Lowers both PTH and calcium simultaneously
• Particularly effective in CKD patients
• Start at 30 mg daily, titrate based on calcium and PTH response

Parathyroidectomy should be considered if 3:

• Medical management fails to control hypercalcemia
• PTH remains persistently >800 pg/mL despite therapy
• Symptomatic hypercalcemia recurs
• Patient has good surgical candidacy
• Observational data suggest parathyroidectomy may have mortality benefit over calcimimetics alone in dialysis patients 3

Regarding Future Osteoporosis Management:

Do NOT resume denosumab in this patient. The risks outweigh benefits because:

• Denosumab causes profound hypocalcemia and secondary hyperparathyroidism in CKD, with risks increasing as kidney function declines 1
• Your patient already has tertiary hyperparathyroidism with hypercalcemia—denosumab would create dangerous calcium fluctuations 2
• Case reports document severe calcium swings (hypocalcemia followed by rebound hypercalcemia) when denosumab is used in CKD patients with elevated PTH 2, 4

Alternative osteoporosis management after PTH control:

• Once tertiary hyperparathyroidism is treated and calcium normalizes, consider zoledronic acid instead 5
• Zoledronic acid has emerging evidence in CKD-associated osteoporosis
• Requires careful monitoring but avoids the severe calcium fluctuations seen with denosumab in CKD

Critical Monitoring Parameters

• Weekly calcium and PTH until stable
• Phosphate levels (watch for hungry bone syndrome if parathyroidectomy performed)
• Kidney function trends
• Bone turnover markers if available

Common Pitfall to Avoid

Do not attribute the hypercalcemia to denosumab alone. While denosumab can paradoxically cause hypercalcemia in rare cases of tertiary hyperparathyroidism 6, 4, the primary driver here is autonomous parathyroid function. The PTH of 175 pg/mL with hypercalcemia indicates the parathyroid glands are functioning independently of normal calcium feedback—this is tertiary hyperparathyroidism requiring specific treatment 3.